Effects of Plasmalogens on Psychological Symptoms in Healthy Me
Not Applicable
- Conditions
- Healthy
- Registration Number
- JPRN-UMIN000032604
- Lead Sponsor
- ational Center of Neurology and Psychiatry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Male
- Target Recruitment
- 72
Inclusion Criteria
Not provided
Exclusion Criteria
1) Subjects with a history of drug or alcohol abuse 2) Subjects with a history of severe head injuries 3) Subjects with a history of severe internal diseases or severe injuries within the past three months 4) Subjects with a history of severe life events occuring within the past three months 5) Subjects with a shell food allergy 6) The lead researcher or collaborative researcher will determine those who are not eligible for this trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Amelioration of depressed mood as evaluated by Beck Depression Inventory-Second Edition (BDI-II) at six weeks and three months after the start of plasmalogen administration
- Secondary Outcome Measures
Name Time Method We aim to assess the following factors at six weeks and three months after the start of the plasmalogen administration. 1. Amelioration of anxiety, sleep, and cognitive functions 2. Changes in plasmalogen levels in blood plasma, serum, and erythrocyte membranes 3. Changes in other biochemical parameters in the blood 4. Changes in salivary cortisol and immunoglobulin A levels